Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986218 + Degarelix |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986218 | BMS986218|BMS 986218 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | BMS-986218 is a 2nd generation antibody that targets CTLA4, resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33). | |
Degarelix | Firmagon | FE200486 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04301414 | Phase I | BMS-986218 + Degarelix Degarelix | Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) | Active, not recruiting | USA | 0 |